Completion of Placing, Retail Offer & Notice of GM

10 March 2026

Physiomics plc

("Physiomics" or the "Company")

Physiomics completes Placing to fund growth opportunities

Launch of WRAP Retail Offer

Notice of General Meeting

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has completed a placing, conditional on certain resolutions being passed at a general meeting of the Company (the "General Meeting") and admission to trading on AIM, of, in aggregate, £449,999.88 (gross) from the issue of 149,999,960 new ordinary shares (the "Placing Shares") at an issue price of £0.003 per Placing Share (the "Placing Price") through the Company's broker, Hybridan LLP (the "Placing"). The Placing Price represents a discount of approximately 33.33 per cent. to the mid-market closing price of an existing ordinary share on 9 March 2026 (being the latest practicable date prior to this announcement).

The Company will also shortly be launching a retail offering to the Company's existing shareholders to raise up to an additional £49,999.98 (or such other amount as agreed by the Company) by way of the issue of a further 16,666,660 new ordinary shares (or such other number as agreed) (the "WRAP Retail Offer Shares") at the Placing Price.

In order to further develop its business and continue its growth trajectory, the Company is raising funds to carry out the following activities and for general working capital:

·    Consulting Services (Modelling & Simulation and Biometrics)

o  Investment in business development and marketing to expand offering across both service lines, including further development of later clinical phases and engagement of large biopharmaceutical companies and contract research organisations; and

o  Expansion of internal capabilities to support both services, including development of new processes and data management solutions to support the expanding offerings.

·    Personalised Medicine Tool Development

o  Continue development of the Company's Personalised Dosing Software.

·    Corporate

o  Exploration of strategic options to accelerate growth of modelling and biometrics services and creation of new service-lines.

The Company has made significant progress since its last placing in February 2025, including:

·    Reporting a 46% year-on-year growth of total income for the financial year ending 30 June 2025 and reporting a record half-year for total income for the six-month period ending 31 December 2025. To date in FY26, the Company has twice exceeded its best monthly revenue in comparison to FY 2025 with one month achieving over £110k.

·    Appointment of Mr Jesse Thissen as Head of Biometrics and the Company's first four contract awards for this new service line.

·    Continued expansion of the modelling and simulation service line into new therapeutic areas, with projects supporting the development of new drugs targeting arthritis, chronic obstructive pulmonary disease, coeliac disease, and infectious diseases.

·    Continued diversification of client base, whilst still winning new business with long-standing relationships such as Numab Therapeutics.

·    Implementation of the Company's Personalised Dosing Software onto the DoseMeRx platform and expanded relationship with DoseMe Inc.

·    One peer-reviewed scientific article was published in partnership with Ankyra Therapeutics, accompanied by several thought leadership pieces and blog posts.

Retail Offering:

The Company is pleased to announce that a retail offer to existing shareholders will be shortly launched via the Winterford Retail Access Platform ("WRAP"), to raise up to an additional £49,999.98 (or such other amount as agreed by the Company) (the "WRAP Retail Offer"), through the issue of up to 16,666,660 new ordinary shares (or such other number as agreed) (the "WRAP Retail Offer Shares"), at the Placing Price.

The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the Placing. For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. Completion of the WRAP Retail Offer is conditional, inter alia, upon the completion of the Placing, but completion of the Placing is not conditional on the completion of the WRAP Retail Offer. The WRAP Retail Offer is conditional on the WRAP Retail Offer Shares being admitted to trading and certain resolutions being passed at the General Meeting.

The Company values its shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom the opportunity to participate in its fundraising.

The WRAP Retail Offer is expected to close at 4.30 p.m. on 12 March 2026.

Admission and Total Voting Rights

The Placing and WRAP Retail Offer are condition on, inter alia, certain resolutions being passed at the General Meeting. The resolutions include: (i) authority to reduce the nominal value of the Company's ordinary shares to accommodate the Placing Price; (ii) authority, under section 551 of the Companies Act 2006 to allot the Placing Shares and WRAP Retail Offer Shares; and (iii) authority to allot the Placing Shares and WRAP Retail Offer Shares for cash as if section 561 of the Companies Act 2006 did not apply to such allotment. The General Meeting will be held on 7 April 2026.

Application will be made for the Placing Shares to be issued pursuant to the Placing and the WRAP Retail Offer Shares to be issued pursuant to the WRAP Retail Offer and each to be admitted to trading on AIM and dealing is expected to commence on or around 8 April 2026 ("Admission"). A further announcement regarding the enlarged issued share capital for the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules will be made following completion of the Placing and the WRAP Retail Offer.

Notice of General Meeting

The Company also announces that it will be posting a notice convening a general meeting of the Company ("Notice of GM") to be held at 10.00 a.m. on 7 April 2026 at Copthorne Hotel Slough-Windsor, Cippenham Lane, Slough, Berkshire, SL1 2YE.

The general meeting is being convened to obtain authority from shareholders to issue and allot shares relating to the placing and WRAP Retail Offer, as announced today.

Shareholders will shortly be sent either printed copies of the Notice of GM or a letter notifying them that the Notice of GM is available on the Company's website, depending on the preferences they have expressed to the Company's registrar.

A copy of the Notice of GM, containing further details of the resolutions to be proposed at the meeting will be made available today on the Company's website at www.physiomics.co.uk/investors/corporate-documents/. 

Dr Peter Sargent, CEO, commented:

"We want to thank our loyal and new shareholders for their support.  Over the last twelve months, Physiomics has continued its growth journey and I am proud that the Company has successfully expanded its offering, with the recent launch of Biometrics service line as well as the expansion of its pre-existing modelling and simulation service line. This expansion of services, along with continued diversification of our client base, is testament to the quality and flexibility we provide our clients and the impact our services bring to their drug development efforts. The Company's revenue profile is improving with a more diverse pipeline and significant visibility of future income. In the last two years, the Company has had five new clients that have come back more than once, helping our business increase the share of revenues which are repeat.   

The Directors believe that this growth will continue and that the Company is on track to meet market expectations for this current year, which would represent a record year for total income  of 27% growth based on market expectations.

With this latest round of funding, investment is being made in key growth initiatives across the business to continue our growth trajectory by investing further in business development and marketing, as well as the exploration of transformational opportunities that will accelerate growth."

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain.

The Directors of the Company accept responsibility for the content of this announcement.

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.